Cheryl N. McMahill-Walraven, MSW, PhD

Executive Director-Safety Surveillance & Collaboration
CVS Health

Poster(s):

• (100) Trends in Clinical Characteristics and Prescribing Patterns for GLP-1 Receptor Agonists and GIPs, 2015–2023
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (254) Enhancing US Lyme Disease Detection in Claims Data: Identifying Acute and Disseminated Disease
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (261) Framework for Public-Private Partnerships for Real-World Data Exchange of Immunizations Records for Public Health Surveillance
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (275) Linkage of Mother and Infant Records using Commercial Claims Data within the Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (347) Interim Utilization Results from a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (352) Safety of Ancestral Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (358) Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 months and Older in the United States
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (CSPOT20) Adherence Differences Between Self-Administered and Provider-Administered Biologics Among Patients with Rheumatoid Arthritis During the COVID-19 National Emergency
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST